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Summary The capacity to detect t(14;18) breakpoints in non-Hodgkin's lymphoma (NHL) peripheral blood
and bone marrow was studied by DNA PCR. We studied 33 patients with follicular lymphoma (FL) (Working
Formulation subtypes B, C, D) and 38 patients with intermediate-grade NHL (subtypes F, G). In the FL
subgroup, 86% of the morphologically-positive bone marrow patients had amplifiable t(14;18) breakpoints by
PCR. Remarkably, of 19 FL patients with 'negative' bone marrows, 11 (58%) were PCR-positive. In addition,
half of the early clinical stage patients (I and II) had detectable breakpoints in their bone marrow DNA.
Samples from NHL patients with intermediate-grade disease exhibit the same phenomena but at a con-
siderably lower frequency. Paired peripheral blood and bone marrow samples were available at diagnosis in a
subset of 56 patients. The concordance between bone marrow and peripheral blood PCR findings was high,
with peripheral blood of 55/56 showing the same PCR results as the corresponding bone marrow.
The t(14;18) (q32;ql) chromosomal translocation is a consis-
tent feature of follicular lymphoma (FL). Approximately
85% of FL patients and one-third of patients with diffuse
large-cell lymphoma (DLCL) carry the t(14;18) (q32;q21)
translocation in tissue specimens, as judged by cytogenic and
molecular studies (Yunis et al., 1982; Lee et al., 1987a; Weiss
et al., 1987; Ngan et al., 1988; Aisenberg et al., 1988). This
translocation results in the juxtaposition of the bcl-2 proto-
oncogene located on chromosome 18 with the immuno-
globulin heavy chain gene (JH) on chromosome 14 (Tsu-
jimoto et al., 1984; Bakhshi et al., 1985; Cleary et al., 1986a).
The breakpoints occur at two sites on chromosome 18: the
'major breakpoint region' (MBR) and a 'minor cluster
region' (mcr) (Tsujimoto et al., 1985; Cleary & Sklar, 1985;
Cleary et al., 1986b; Ngan et al., 1989). New evidence sug-
gests that the bcl-2 gene may play a role in suppressing
programmed cell death within lymphoid cells (McDonnell et
al., 1989; Hockenbery et al., 1991). The fact that most trans-
locations cluster in an extremely small area has encouraged
investigators to analyse the t(14;18) breakpoint by the
polymerase chain reaction (PCR) (Lee et al., 1987b;
Crescenzi et al., 1988; Stetler-Stevenson et al., 1988; Ngan et
al., 1989; Cotter et al., 1990). The tumour marker can be
detected with high sensitivity by using primers specific to the
bcl-2/JH translocated gene sequences, and one tumour cell
can be detected among 105- 106 normal cells (Crescenzi et al.,
1988; Stetler-Stevenson et al., 1988).
Bone marrow involvement in NHL is common in certain
subtypes at onset or during the course of the disease, and
patients with bone marrow involvement run a substantial risk
of tumour recurrence (Dick et al., 1974; Rosenberg, 1975;
Stein et al., 1976; Simon et al., 1988). Thus, improved assess-
ment of occult lymphoma cells in this site, especially in
early-stage NHL patients, could be very useful for staging
and managing treatment of the disease. To this end, we have
assessed the usefulness of bcl-2/JH PCR analysis on the
peripheral blood and bone marrow of follicular lymphoma
and intermediate-grade NHL patients.
Material and methods
Patients andsamples
Blood and/or bone marrow samples to be analysed by PCR
were collected from patients with non-Hodgkin's lymphoma
(NHL) during the period from 1989 to 1991 by the depart-
ment of medical oncology in Ticino, Switzerland. For this
study, bone marrow samples were available from 71 patients:
33 were classified as follicular lymphoma, subtypes B, C and
D, and 38 were classified as intermediate-grade NHLs, sub-
types F and G according to the Working Formulation (WF)
(The non-Hodgkin's lymphoma pathologic classification pro-
ject, 1982). Mononuclear cells were separated by Ficoll-
Hypaque centrifugation (Ficoll-Hypaque separating solution,
Biochrom KG, Berlin) and red cells were removed with lysis
buffer (0.32 M sucrose, 10 mM Tris-HCI, 5 mM MgCl2, 1%
Triton X-100) (Higuchi, 1989). The pellet containing
mononuclear cells was resuspended (5 x 106 cells per I ml) in
100mM NaCl, 25mM EDTA, 0.5% SDS and 200 sgml-'
proteinase K (Sigma, St Louis, MO) and incubated overnight
at 37°C. DNA was extracted by phenol-chloroform and
precipitated with ethanol. Eight samples with small numbers
of cells were prepared by resuspension in digestion mixture
(1 x PcR buffer, 0.25% Tween 20, 0.6 yl of 10 mg ml-' pro-
teinase K per 100;LI) at a concentration of 5 x I05 cell ml-'
and incubated at 56°C for 2'h followed by a 95°C 20 min
inactivation step to inhibit proteinase K (Kawasaki, 1990).
Polymerase chain reaction (PCR)
One and a half ttg of sample DNA were added to a reaction
mixture which contained 25 ymol 1 I of each primer,
100imol 1' of each dNTP, 1.5 U Taq polymerase (Cetus,
Emeraville, CA) 1 x PCR buffer (50 mmol 1I KCI,
10mmoll-' Tris-Cl, 1.5mmoll' MgCI2 in a 50yl total
volume. The PCR was performed in a Perkin Elmer Cetus
thermal cycler, using as primers the oligonucleotide: 5'-CTC
GGA TCC AGT TGC TTT ACG TGG CCT GT-3' for the
MBR or 5'-GAC TCC TTT ACG TGC TAC C-3' for the
mcr and 5'-GGA AGC TTA CCT GAG GAG ACG GTG
ACC-3' for the JH consensus region.
After an initial denaturation step at 94'C for 5 min, PCR
for either MBR or mcr was performed under the following
conditions: denaturation at 94°C 30 seconds, annealing at
56°C 30 seconds and polymerisation at 72'C 30 seconds for
40 cycles. For experiments detecting the MBR breakpoint,
DNA from a NHL B-cell line DoHH2 was used as the
positive control (Kluin-Nelemans et al., 1991). Four highly
selected positive DNA samples from NHL patients served as
positive controls for the mcr breakpoint. We closely followed
the guidelines for preventing contamination proposed by
Kwok & Higuchi (1989), and because of the extreme sen-
sitivity of the PCR system, considerable effort was devoted to
running numerous controls. We evaluated the specificity of
the PCR assays by testing them against 42 DNA samples
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from leukaemic controls, healthy subjects and a group of
patients with other diseases. All these samples were negative.
Several reagent controls were run during each experiment. In
addition to the positive controls, well characterised negative
DNA samples were routinely included in each run. Samples
negative for both breakpoints were checked for intactness of
DNA by amplifying a 250 bp fragment of the P53 gene.
Liquidhybridisation
Liquid hybridisation (Ehrlich et al., 1990) was performed in a
total volume of 40pl using 20ftl of PCR product, 4pl of salt
solution (1.5M NaCl, 25 mM EDTA), and 15,000 cpm of
'-32P-ATP labelled internal probe, 5'CAC AGA CCC ACC
CAG AGC CCT CCT GCC CTC CTT CCC GCG GG-3'
for the MBR and 5'-CTC GGA TCC AGT TGC TlTT ACG
TGG CCT GT-3' for the mcr. For hybridisation, samples
were denatured at 98°C for 5 min and annealed at 72°C for
15 min. Twenty jil of the hybridised product was loaded on a
3% NuSieve/0.8% agarose gel containing 0.5 x TBE buffer.
After electrophoresis the gel was dried down under low heat
vacuum, and subsequently analysed by autoradiography.
Exposure times were generally between 2
and 6 h.
Results
Sensitivity ofthe assay
Serial dilution experiments using the DoHH2 cell line demon-
strated that tumour cells can be detected by PCR in a
dilution of at least 10-4 on ethidium-bromide stained agarose
gels. Liquid hybridisation increased this sensitivity up to at
least 10-6.
Table I Comparison of bone marrow histology vs PCR in 33
follicular lymphoma patients (WF: B,C,D)a
Histology No. ofpatients PCR positive
Bone marrow positive 14 12 (86%)
Bone marrow negative 19 11 (58%)
Total 33 23 (70%)
aWF: Working Formulation.
B-follicular, predominantly small cleaved cells.
C-follicular, mixed, small cleaved and large cells.
D-follicular, predominantly large cells.
pos. - FL patients - neg.
bp
230-
1 2 3 4 5 6 7
Figure 1 PCR detection for t(14;18) mbr in bone marrows with
negative histology from follicular lymphoma (FL) patients. Autoradiography of annealed products shows strong positive sig- nals over 4 of 5 morphologically negative bone marrow samples (lane 2-6). Pos.: positive control (lane 1). Neg.: negative control
(lane 7). Note variation in amplified product size when compared
to each other and the positive control.
Bone marrow histology vs bone marrow PCR detection
Bone marrow from 71 low- or intermediate-grade NHL
patients was tested by PCR for mbr and mcr breakpoints.
Samples negative for both t(14;18) breakpoints were further
tested for intactness of DNA by amplifying a short segment
of P53 gene. Thirty-three bone marrows were available from
follicular NHL (WF B, C and D) patients and Table I
summarises the results of PCR testing. Twelve of fourteen
patients whose bone marrow was positive by histology were
also PCR positive (86%). We found in 19 morphologically
'negative' bone marrows a further 11 patients (58%) who
were clearly t(14;18) positive by PCR. Representative PCR
products from four of the patients with morphologically
negative bone marrows are shown in Figure 1. Table II
shows that when the same group of 33 follicular lymphoma
patients are staged using the Ann Arbor system, many of the
early-clinical-stage patients manifest the t(14;18) marker in
their bone marrow.
The PCR assay detected the t(14;18) in 13 (34%) of 38
patients with intermediate-grade NHLs (WF F and G).
When bone marrow histology was negative PCR demon-
strated neoplastic cells in approximately 28% of samples
(Table III).
Table III Incidence of bone marrow involvement by PCR in 38
diffuse NHL patients (WF: F,G)a
Histology No. ofpatients PCR positive
Bone marrow positive 20 8 (40%) Bone marrow negative 18 5 (28%)
Total 38 13 (34%)
aWF: Working Formulation.
F-diffuse, mixed, small and large cells.
G-diffuse, large cells.
Peripheral bloodcorrelate
We attempted to determine the concordance rate between the
peripheral blood-a more accessible tissue- and the bone
marrow PCR assay. Fifty-six paired peripheral blood and bone marrow samples were tested by PCR and the concord-
ance was striking, with the peripheral blood samples from 55 patients uniformly showing the same result as the corres-
ponding bone marrow. Although these findings suggest that
Table II Bone marrow PCR vs histology and clinical stage of 33 follicular
lymphomas patients (WF: B,C,D)a
Clinical stage No. ofpatients PCR positive BM histology positive
I 3 1 (33%) 0
II 6 3 (50%) 0
III 6 4 (67%) 0
IV 18 15 (83%) 14 (78%)
aWF: Working Formulation.
B-follicular, predominantly small cleaved cells.
C-follicular, mixed, small cleaved and large cells.
D-follicular, predominantly large cells.924 R. YUAN et al.
peripheral blood and bone marrow findings are closely cor-
related this may no longer be true after treatment. We
observed three patients with FL in whom peripheral blood
became t(14;18)-negative following chemotherapy (single
agent chlorambucil) while the bone marrow remained clearly
positive. These data are very preliminary and a large number
of patients will be followed prospectively.
Discussion
The utility of molecular monitoring in the assessment of
lymphoma patients is still controversial: conflicting results
have been published on the prognostic significance of bcl-2
protein expression and/or bcl-2 gene rearrangements (Yunis
et al., 1989; Price et al., 1991; Pezzella et al., 1992).
In this study we assessed the usefulness of bcl-2/JH PCR
as a means for improving the detection of lymphoma cells in
the bone marrow of follicular lymphoma and intermediate-
grade NHL patients. Half of the early-stage FL patients with
morphologically normal marrow had amplifiable break-
points, and we found that the marrow compartments, even in
stage I and II patients, frequently contained lymphoma cells
when tested by PCR. Thus bcl-2/JH PCR assessment in
early-stage FL can result in upstaging many patients and
may be of considerable interest to the clinician.
The possibility of an easy detection of bcl-2/JH rearrange-
ment may also be useful in diffuse large-cell or mixed-cell
lymphomas where it may be associated with a relatively poor
prognosis (Yunis et al., 1989) and may indicate a mor-
phological transformation from a FL to a more aggressive
histologic subtype (Lee et al., 1987a). In the intermediate-
grade patients we found bcl-2/JH rearrangements in approx-
imately 34% of bone marrow and peripheral blood samples.
This finding is consistent with other studies reporting an
overall frequency of approximately 20%-40% of the t(14;18)
in this group ofpatients (Yunis et al., 1982; Lee et al., 1987a;
Aisenberg et al., 1988; Yunis et al., 1989; Lambrechts et al.,
1992).
The most interesting finding in our study was the striking
correlation between bcl-2/JH positivity in the peripheral
blood and the corresponding bone marrow sample. Paired
samples showed concordance in virtually all cases. We believe
that our data accurately reflect the status of the tissue sam-
ples and are not a consequence of cross-contamination or
false positive results, because in all cases where bone marrow
DNA was negative, the corresponding peripheral blood sam-
ple contained no detectable specific PCR product. In addi-
tion, the migration patterns on agarose gel suggested that the
results were not due to contamination because the size of the
PCR products varied from patient to patient. This observa-
tion suggests that the peripheral blood-a readily accessible
tissue-provides considerable ancillary information in early-
stage follicular lymphoma patients. Peripheral blood may in
fact provide nearly the same information as the bone marrow
aspirate. Therefore, it may reduce the need for more invasive
examinations. Similar results, with a lesser degree ofconcord-
ance between bone marrow and peripheral blood analysis,
have recently been published (Hickish et al., 1991) indicating
the PCR can be an effective means for clinical monitoring of
low-grade lymphomas. However, the clinical significance of
detecting minimal disease in bone marrow by PCR has still
to be established and will require prolonged follow-up
because of the natural history of FL with a median survival
than can exceed 8 years in advanced stages. Serial samples
from patients undergoing chemotherapy suggest that after
treatment the peripheral blood and bone marrow may show
divergent results and a larger number of patients will be
followed prospectively to confirm this very preliminary find-
ing whose biological significance is yet unclear. One pos-
sibility is that circulating cells with the t(14;18) have altered
properties (e.g. loss of adhesion) modifying their clinical
behaviour. The clinical relevance of the persistence of PCR-
detectable neoplastic cells in the blood and in the bone
marrow may also be different for the different types of
lymphomas. Further studies on serial samples from patients
are needed to determine the usefulness of bcl-2/JH PCR
detection post-therapy. In fact, it has recently been shown
that aggressive chemotherapy often fails to eradicate bcl-2/
JH-positive cells from the marrow even when this becomes
morphologically negative (Gribben et al., 1991) and that
circulating cells carrying t(14;18) may be found in some long
remissions of advanced FL (Price et al., 1991; Lambrechts et
al., 1992) but not in patients initially with truly localised
disease (Price et al., 1991). An accurate quantification of the
PCR analysis would be very helpful for clarifying many
issues, development of reliable procedures is ongoing.
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